Navigation Links
Recruitment Completed in Ofatumumab NHL Pivotal Study
Date:9/23/2008

Summary: Genmab has Completed Recruitment of Patients in the Phase III

Study of Ofatumumab in Rituximab Refractory Follicular NHL

COPENHAGEN, September 23 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of patients in the pivotal Phase III study of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular non-Hodgkin's lymphoma (NHL). Eighty-one patients receiving treatment at the 1000 mg dose level of ofatumumab have been recruited in the study. Data from these patients will be included in the primary efficacy analysis. An additional 31 patients were recruited at a 500 mg dose level prior to amending the study design to include only one dose. Data from these patients will be evaluated for safety and supportive efficacy analysis.

"We have now recruited the last patient into the study and keenly await the results which we hope will show a benefit for follicular NHL patients who need a new treatment option," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Ofatumumab is an investigational, new generation, human monoclonal antibody that targets a distinct membrane proximal, small loop epitope (specific binding site)of the CD20 molecule on the surface of B-cells. Ofatumumab is being developed to treat CLL, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved for sale in any country.

About the trial

Patients in this study will receive one infusion of 300 mg of ofatumumab followed by 7 weekly infusions of 1000 mg of ofatumumab. Disease status will be assessed every 3 months until month 24.

The objective of the study is to determine the efficacy and safety of ofatumumab in rituximab refractory follicular NHL. The primary endpoint of the study is objective response
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
3. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
4. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
5. Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment
6. Argonauta Assist(TM)ance: Argonauta Communications Strives to Enhance Site-Based Recruitment Efforts
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
9. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
10. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
11. Genmab Reaches Milestone in Ofatumumab Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/10/2014)... , July 11, 2014  Major advances in ... cancer are being highlighted in a three-day Oncology ... from 10-12 July, 2014.  Renowned national and international cancer ... best practices and exchange knowledge on modern technologies ... and efficient. The Summit will ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... Calif., Jan. 5, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... Officer of BioMarin, will present a company update at the ... Monday, January 10, 2011 at 2:30 p.m. PT.   ... the conference call via the investor section of the BioMarin ...
... 5, 2011 Ikaria, Inc. today announced that the ... (nitric oxide) for inhalation an additional six months of ... exclusivity for INOMAX from January 2013 to July 2013. ... clinical trials of INOMAX in pre-term infants at risk ...
Cached Medicine Technology:BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference 2FDA Extends Marketing Exclusivity for INOMAX® 2FDA Extends Marketing Exclusivity for INOMAX® 3
(Date:7/12/2014)... CA (PRWEB) July 12, 2014 For those ... are bodies can readily absorb the nutrients in food. The ... particles that are small enough to be absorbed by human ... team, a lack of enzymes in regular food is the ... a product that was started by Michelle DelPresto, a mother ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major Developed ... PCCs and Recombinant Products to Drive Market,” which ... in the US, UK, France, Germany, Italy, Spain, ... of market size for 2013, along with market ... that are being treated using the five major ...
(Date:7/12/2014)... As reported in this July 1st ... Technology), the June 25th, 2014 Supreme Court ruling in Riley ... It was also met with both cheers and jeers ... was seen from an individual privacy perspective, or a law ... is now precedent which will require law enforcement officials to ...
(Date:7/12/2014)... July 12, 2014 Dubai is buzzing ... legend is heading to the UAE. The National ... will be in the UAE from 28-31 October to ... support of diabetes awareness. The event is being organized ... and event management company based in Dubai. The announcement ...
(Date:7/12/2014)... Texas (PRWEB) July 12, 2014 ... Breastfeeding Made Simple as a valuable new resource for ... roughly two-thirds of American women work away from their ... sources touting the benefits of breastfeeding, but often feel ... to nurse their babies. With its evidence-based insights, and ...
Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2
... for the Cure,s Global Promise, DALLAS, Oct. ... the,leader of the global breast cancer movement, is ... Hewko as vice president of,international, reporting to Komen ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ), Hewko will guide ...
... Members who choose Regence,s,Health Savings Account (HSA) will ... company has added U.S. Bank as a banking partner. ... care banking,and its strong consumer track record., "We ... and,brand like U.S. Bank to offer our members the ...
... Barnett, London, Ontario, receives the Karolinska Stroke Award for ... SEK. The laureate will receive the prize from the ... Stroke Update meeting in Stockholm November 17, 2008. ... award. The Karolinska Institutet also awards the Nobel ...
... ANGELES, Oct. 29 George Abercrombie, president ... address Los Angeles,business leaders at the National ... He plans to tell them,that the threat ... challenges,unlike those anticipated with traditional emergency preparedness ...
... Cojocaru forms Team Cojo to fight PKD, ... own life-saving,kidney transplant, fashion critic and Entertainment Tonight ... the 12.5 million people,worldwide affected by Polycystic Kidney ... world,s most common, life-threatening genetic,diseases, affecting more people ...
... Health Literacy Month, recognized in October, promotes ... information. According to the National Assessment of Adult ... health literacy - skills needed to manage their ... the focus of an ongoing study at the ...
Cached Medicine News:Health News:Susan G. Komen for the Cure(R) Strengthens Global Mission With Addition of Vice President, International 2Health News:Susan G. Komen for the Cure(R) Strengthens Global Mission With Addition of Vice President, International 3Health News:Regence Teams With U.S. Bank to Offer New Health Savings Account Solution 2Health News:Dr. Henry Barnett becomes first person outside Europe to receive Karolinska Stroke Award 2Health News:CEO to Address Los Angeles Business Leaders About Developing Pandemic and Business Continuity Plans 2Health News:CEO to Address Los Angeles Business Leaders About Developing Pandemic and Business Continuity Plans 3Health News:Cojo to Hit the Streets of LA for 2008 Walk for PKD 2Health News:$8.6 million grant to MU will fund efforts to improve health literacy, health outcomes 2
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
Inquire...
Inquire...
Medicine Products: